Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA33890 in first-line metastatic microsatellite stable colorectal cancer
NCT07284849Phase 3Recruiting
- Sponsor
- Incyte
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 22
01
Overview
A Phase 3 trial of INCA-33890 in colorectal cancer (CRC), sponsored by Incyte. Started Mar 2026; status: recruiting.
02
Drugs
INCA-33890
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07284849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284849.